PT  - JOURNAL ARTICLE
AU  - Flament, H.
AU  - Rouland, M.
AU  - Beaudoin, L.
AU  - Toubal, A.
AU  - Bertrand, L.
AU  - Lebourgeois, S.
AU  - Gouda, Z.
AU  - Rousseau, C.
AU  - Soulard, P.
AU  - Hurtado-Nedelec, M.
AU  - Luce, S.
AU  - Bailly, K.
AU  - Andrieu, M.
AU  - Boitard, C.
AU  - Vallet-Pichard, A.
AU  - Gautier, JF.
AU  - Ajzenberg, N.
AU  - Terrier, B.
AU  - Pene, F.
AU  - Ghosn, J.
AU  - Yazdanpanah, Y.
AU  - Visseaux, B.
AU  - Descamps, D.
AU  - Timsit, JF.
AU  - Monteiro, R.C.
AU  - Lehuen, A.
TI  - Outcome of SARS-CoV-2 infection linked to MAIT cell activation and cytotoxicity: evidence for an IL-18 dependent mechanism
AID  - 10.1101/2020.08.31.20185082
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.31.20185082
4099  - http://medrxiv.org/content/early/2020/09/02/2020.08.31.20185082.short
4100  - http://medrxiv.org/content/early/2020/09/02/2020.08.31.20185082.full
AB  - Immune system dysfunction is paramount in Coronavirus disease 2019 (COVID-19) severity and fatality rate. Mucosal-Associated Invariant T (MAIT) cells are innate-like T cells involved in mucosal immunity and protection against viral infections. Here, we studied the immune cell landscape, with emphasis on MAIT cells, in a cohort of 182 patients including patients at various stages of disease activity. A profound decrease of MAIT cell counts in blood of critically ill patients was observed. These cells showed a strongly activated and cytotoxic phenotype that positively correlated with circulating pro-inflammatory cytokines, notably IL-18. MAIT cell alterations markedly correlated with disease severity and patient mortality. SARS-CoV-2-infected macrophages activated MAIT cells in a cytokine-dependent manner involving an IFNα-dependent early phase and an IL-18-induced later phase. Therefore, altered MAIT cell phenotypes represent valuable biomarkers of disease severity and their therapeutic manipulation might prevent the inflammatory phase involved in COVID-19 aggravation.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study did not aim to test any treatment.Funding StatementA.L. and R.C.M. laboratories are supported by ANR-11-IDEX-0005-02 Laboratory of Excellence INFLAMEX and Fondation pour la Recherche Medicale (EQU201903007779 to A.L. and EQU201903007816 to R.C.M.). R. C. M. received a Universite de Paris COVID-19 grant. A. L. is also supported by ANR-17-CE14-0002-01, ANR-19-CE14-0020, Fondation Francophone pour la Recherche sur le Diabete. A. L., C. B., A. V.-P. and JF. G. are supported by RHU QUID-NASH (ANR-17-RHUS-009); M. R. and L.Ber. were supported by French Ministry of Research grants, A.T. and Z.G. were supported by RHU QUID-NASH; C. R. was supported by Fondation Francophone contre le Diabete, P. S. was supported by Juvenile Diabetes Research Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committees approved clinical investigations. Informed consent was obtained from each enrolled patient. Patients from Bichat Hospital (Paris, France) were included in the French COVID cohort (NCT04262921). Ethics approval for this cohort was given on February 5th, 2020 by the French Ethics Committee CPP-Ile de France-VI (ID CRB: 2020-A00256-33). This cohort is sponsored by Inserm and supported by the REACTing consortium and by the French Ministry of Health (PHRC n20-0424). Samples from these patients were derived from samples collected in routine care. Patients from Cochin Hospital (Paris, France) were recruited in the setting of the local RADIPEM biological samples collection derived from samples collected in routine care. Biological collection and informed consent were approved by the Direction de la Recherche Clinique et Innovation (DRCI) and the French Ministry of Research (N2019-3677). Investigations with control patients from QUID-NASH were approved by Comite de Protection des Personnes de Sud Mediterranee (V) #18.021, N of QUID project registration: 2018-A00311-54.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code generated during this study will be available before publication in a repository. Access code will be given upon request at agnes.lehuen{at}inserm.fr